Biocon Biologics appoints Neelkanth Chandgothia as new Global Head - Corporate Finance
Biocon Biologics has announced the appointment of Neelkanth Chandgothia as its new Global Head - Corporate Finance, reporting to the CFO.
Neel brings with him over 20 years of rich experience in finance, strategy, and leadership, and has successfully led high-value transformations across diverse industry stalwarts like PwC, EY, airtel, and Jubilant FoodWorks Ltd.
At Biocon Biologics, he will help strengthen and expand the company's Corporate Finance function, driving financial planning, budgeting, tax, forecasting, treasury management, and compliance, while further strengthening financial controls and governance practices across the organization, fueling global growth.
Kedar Upadhye, CFO, said, “I look forward to Neel’s strategic vision, problem-solving approach, and ability to implement innovative financial solutions contributing to our mission of transforming healthcare and changing people's lives for the better through biosimilars.”
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated, global biosimilars company. Biocon Biologics has commercialized 10 biosimilars from its portfolio which are addressing the patients’ needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other noncommunicable diseases.
Next Story